Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an In Vitro Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae
暂无分享,去创建一个
J. Ariza | F. Tubau | O. Murillo | A. Ribera | J. Gómez-Junyent | E. Benavent | R. Rigo-Bonnin | Cristina El-Haj
[1] J. Ariza,et al. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. , 2019, International journal of antimicrobial agents.
[2] E. Roilides,et al. Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms , 2019, Antimicrobial Agents and Chemotherapy.
[3] C. Clancy,et al. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance , 2018, Antimicrobial Agents and Chemotherapy.
[4] N. Lloberas,et al. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm. , 2018, International journal of antimicrobial agents.
[5] L. Leibovici,et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.
[6] A. Spormann,et al. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms , 2017, The Journal of antimicrobial chemotherapy.
[7] E. Kara,et al. Investigation of the effects of various antibiotics against Klebsiella pneumoniae biofilms on in vitro catheter model , 2017 .
[8] C. Giske,et al. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments. , 2016, The Journal of antimicrobial chemotherapy.
[9] R. Hancock,et al. Antibiofilm Peptides: Potential as Broad-Spectrum Agents , 2016, Journal of bacteriology.
[10] N. Høiby,et al. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions , 2015, Pathogens and disease.
[11] Brian T. Tsuji,et al. Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria , 2015, Infectious Diseases and Therapy.
[12] Suzana M. Ribeiro,et al. Antibiofilm Peptides Increase the Susceptibility of Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates to β-Lactam Antibiotics , 2015, Antimicrobial Agents and Chemotherapy.
[13] Á. Soriano,et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[14] J. Li,et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. , 2014, The Journal of antimicrobial chemotherapy.
[15] Grace C. Lee,et al. Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae , 2013, Journal of clinical medicine research.
[16] A. Oliver,et al. High β-Lactamase Levels Change the Pharmacodynamics of β-Lactam Antibiotics in Pseudomonas aeruginosa Biofilms , 2012, Antimicrobial Agents and Chemotherapy.
[17] D. Paterson,et al. The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model , 2012, Antimicrobial Agents and Chemotherapy.
[18] N. Høiby,et al. In Vivo Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem in Pseudomonas aeruginosa Biofilm Infection , 2012, Antimicrobial Agents and Chemotherapy.
[19] Brian T. Tsuji,et al. Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model , 2011, Antimicrobial Agents and Chemotherapy.
[20] A Forrest,et al. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.
[21] Á. Soriano,et al. Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis , 2009, Antimicrobial Agents and Chemotherapy.
[22] J. Turnidge,et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. , 2008, The Journal of antimicrobial chemotherapy.
[23] T. Tolker-Nielsen,et al. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes , 2008, Molecular microbiology.
[24] M. Hamilton,et al. Statistical assessment of a laboratory method for growing biofilms. , 2005, Microbiology.
[25] Paul Stoodley,et al. Bacterial biofilms: from the Natural environment to infectious diseases , 2004, Nature Reviews Microbiology.
[26] D. Nicolau,et al. Pharmacokinetics of High-Dose Meropenem in Adult Cystic Fibrosis Patients , 2001, Chemotherapy.
[27] M. R. Brown,et al. Biofilms and beta-lactam activity. , 1998, The Journal of antimicrobial chemotherapy.
[28] R. Eng,et al. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria , 1991, Antimicrobial Agents and Chemotherapy.